The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis
Open accessAbstract
BACKGROUND: The Mayo score and a noninvasive 9-point partial Mayo score are used as outcome measures for clinical trials assessing therapy for ulcerative colitis (UC). There are limited data assessing what defines a clinically relevant change in these indices. We sought to assess what constitutes a clinically meaningful change in these indices using data from a recently completed placebo-controlled clinical trial. METHODS: In all, 105 patients were enrolled in a 12-week randomized, placebo-controlled trial assessing rosiglitazone for treatment of mild to moderate UC. We compared the change in the Mayo score, the partial Mayo score, and a 6-point score composed just of the stool frequency and bleeding components of the Mayo score to the patient's perception of disease activity at week 0 and week 12. Optimal cutpoints were calculated as the maximal product of sensitivity and specificity. RESULTS: Each index was strongly correlated with the patient's rating of disease activity at week 12 (Spearman correlations 0.61-0.71, P < 0.0001 for all correlations). The maximal product of sensitivity and specificity to identify patient reported improvement of disease activity was achieved using cutpoints for change of 2.5 for the Mayo score (sensitivity 88%, specificity 80%), 2.5 for the partial Mayo score (sensitivity 88%, specificity 87%), and 1.5 for the 6-point score (sensitivity 88%, specificity 80%). CONCLUSIONS: The partial Mayo score and the 6-point score composed solely of the stool frequency and bleeding components performed as well as the full Mayo score to identify patient perceived clinical response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Measurement of Observer Agreement for Categorical Data
Landis, J. R., & Koch, G. G. (1977) · Biometrics · doi:10.2307/2529310 · Cited by 81,148
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050516 · Cited by 3,902
Self-citationIs the Placebo Powerless?: An Analysis of Clinical Trials Comparing Placebo with No Treatment
Hróbjartsson, A., & Gøtzsche, P. C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105243442106 · Cited by 1,503
A simple clinical colitis activity index
Walmsley, R. S., Ayres, R. C. S., Pounder, R. E., & Allan, R. N. (1998) · Gut · doi:10.1136/gut.43.1.29 · Cited by 1,306
D’Haens, G., Sandborn, W. J., Feagan, B. G., Geboes, K., Hanauer, S. B., Irvine, E. J., Lémann, M., Marteau, P., Rutgeerts, P., Schölmerich, J., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.12.038 · Cited by 1,207
Mucosal Healing in Inflammatory Bowel Disease: Results From a Norwegian Population-Based Cohort
Frøslie, K. F., Jahnsen, J., Moum, B. A., & Vatn, M. H. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.051 · Cited by 1,121
Irvine, E. J., Feagan, B., Rochon, J., Archambault, A., Fedorak, R. N., Groll, A., Kinnear, D., Saibil, F., & McDonald, J. W. D. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90585-1 · Cited by 712
Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis
Higgins, P. D. R., Schwartz, M., Mapili, J., Krokos, I., Leung, J., & Zimmermann, E. M. (2005) · Gut · doi:10.1136/gut.2004.056358 · Cited by 244
Rosiglitazone for Active Ulcerative Colitis: A Randomized Placebo-Controlled Trial
Lewis, J. D., Lichtenstein, G. R., Deren, J. J., Sands, B. E., Hanauer, S. B., Katz, J. A., Lashner, B., Present, D. H., Chuai, S., Ellenberg, J. H., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.12.012 · Cited by 229
Self-citationSu, C., Lichtenstein, G. R., Krok, K., Brensinger, C. M., & Lewis, J. D. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.024 · Cited by 212
Self-citation
Cited by
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Feagan, B. G., Rutgeerts, P., Sands, B. E., Hanauer, S., Colombel, J.-F., Sandborn, W. J., Van Assche, G., Axler, J., Kim, H.-J., Danese, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215734 · Cited by 2,888
Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
Kornbluth, A., & Sachar, D. B. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.727 · Cited by 2,023
Johansson, M. E. V., Gustafsson, J. K., Holmén-Larsson, J., Jabbar, K. S., Xia, L., Xu, H., Ghishan, F. K., Carvalho, F. A., Gewirtz, A. T., Sjövall, H., et al. (2014) · Gut · doi:10.1136/gutjnl-2012-303207 · Cited by 1,004
Colombel, J. F., Rutgeerts, P., Reinisch, W., Esser, D., Wang, Y., Lang, Y., Marano, C. W., Strauss, R., Oddens, B. J., Feagan, B. G., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.054 · Cited by 919
Self-citationVedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
Sands, B. E., Peyrin-Biroulet, L., Loftus, E. V., Danese, S., Colombel, J.-F., Törüner, M., Jonaitis, L., Abhyankar, B., Chen, J., Rogers, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1905725 · Cited by 754
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis
Sandborn, W. J., Feagan, B. G., D’Haens, G., Wolf, D. C., Jovanovic, I., Hanauer, S. B., Ghosh, S., Petersen, A., Hua, S. Y., Lee, J. H., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2033617 · Cited by 569
OptimalCutpoints: An R Package for Selecting Optimal Cutpoints in Diagnostic Tests
López-Ratón, M., Rodríguez-Álvarez, M. X., Suárez, C. C., & Sampedro, F. G. (2014) · Journal of Statistical Software · doi:10.18637/jss.v061.i08 · Cited by 548
Sturm, A., Maaser, C., Calabrese, E., Annese, V., Fiorino, G., Kucharzik, T., Vavricka, S. R., Verstockt, B., van Rheenen, P., Tolan, D., et al. (2019) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjy114 · Cited by 461
Reliability and Initial Validation of the Ulcerative Colitis Endoscopic Index of Severity
Travis, S. P. L., Schnell, D., Krzeski, P., Abreu, M. T., Altman, D. G., Colombel, J., Feagan, B. G., Hanauer, S. B., Lichtenstein, G. R., Marteau, P. R., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.07.024 · Cited by 457
Self-citationDefining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions
Peyrin-Biroulet, L., Panés, J., Sandborn, W. J., Vermeire, S., Danese, S., Feagan, B. G., Colombel, J.-F., Hanauer, S. B., & Rycroft, B. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.06.001 · Cited by 455
Mills, R. H., Dulai, P. S., Vázquez-Baeza, Y., Sauceda, C., Daniel, N., Gerner, R. R., Batachari, L. E., Malfavon, M., Zhu, Q., Weldon, K., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-021-01050-3 · Cited by 385
Cox, S. R., Lindsay, J. O., Fromentin, S., Stagg, A. J., McCarthy, N. E., Galleron, N., Ibraim, S. B., Roume, H., Levenez, F., Pons, N., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.09.024 · Cited by 382
Nguyen, G. C., Bernstein, C. N., Bitton, A., Chan, A. K., Griffiths, A. M., Leontiadis, G. I., Geerts, W., Bressler, B., Butzner, J. D., Carrier, M., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.042 · Cited by 350
Fritsch, J., Garces, L., Quintero, M. A., Pignac-Kobinger, J., Santander, A. M., Fernández, I., Ban, Y. J., Kwon, D., Phillips, M. C., Knight, K., et al. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.05.026 · Cited by 313
Self-citationChang, J., Leong, R. W., Wasinger, V. C., Ip, M., Yang, M., & Phan, T. G. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.05.056 · Cited by 286
Converging goals of treatment of inflammatory bowel disease from clinical trials and practice
Levesque, B. G., Sandborn, W. J., Ruel, J., Feagan, B. G., Sands, B. E., & Colombel, J.-F. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.08.003 · Cited by 217
Targeting sphingosine-1-phosphate signaling in immune-mediated diseases: beyond multiple sclerosis
Pérez-Jeldres, T., Alvarez-Lobos, M., & Rivera-Nieves, J. (2021) · Drugs · doi:10.1007/s40265-021-01528-8 · Cited by 197
Cook, J., Hislop, J., Adewuyi, T., Harrild, K., Altman, D., Ramsay, C., Fraser, C., Buckley, B., Fayers, P., Harvey, I., et al. (2014) · Health Technology Assessment · doi:10.3310/hta18280 · Cited by 194
Wynne, B., McHugh, L., Gao, W., Keegan, D., Byrne, K., Rowan, C., Hartery, K., Kirschbaum, C., Doherty, G., Cullen, G., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.11.030 · Cited by 188
Gubatan, J., Levitte, S., Patel, A., Balabanis, T., Wei, M. T., & Sinha, S. R. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i17.1920 · Cited by 121
Podlesny, D., Durdevic, M., Paramsothy, S., Kaakoush, N. O., Högenauer, C., Gorkiewicz, G., Walter, J., & Fricke, W. F. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100711 · Cited by 111
Parra, R. S., Chebli, J. M., Amarante, H. M., Flores, C., Parente, J. M., Ramos, O., Fernandes, M., Rocha, J. J., Feitosa, M. R., Feres, O., et al. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i38.5862 · Cited by 92
Hughes, L. D., King, L., Morgan, M., Ayis, S., Direkze, N., Lomer, M. C., Lindsay, J. O., & Whelan, K. (2016) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjv192 · Cited by 84
Yanartas, Ö., Kani, H. T., Bicakci, E., Kilic, I., Banzragch, M., Acikel, C., Atug, O., Kuscu, K., Imeryuz, N., & Akin, H. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s106039 · Cited by 69
“Higher scores mean a worsening of underlying UC disease activity.(24)”
BackgroundByrne, M. F., Panaccione, R., East, J. E., Iacucci, M., Parsa, N., Kalapala, R., Reddy, D. N., Ramesh Rughwani, H., Singh, A. P., Berry, S. K., et al. (2023) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjac152 · Cited by 51
Elkrief, A., Waters, N. R., Smith, N., Dai, A., Slingerland, J., Aleynick, N., Febles, B., Gogia, P., Socci, N. D., Lumish, M., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0498 · Cited by 48
Health-related quality of life of patients with inflammatory bowel disease in Singapore
Min Ho, P. Y., Hu, W., Lee, Y. Y., Gao, C., Tan, Y. Z., Cheen, H. H., Wee, H. L., Lim, T. G., & Ong, W. C. (2019) · Intestinal Research · doi:10.5217/ir.2018.00099 · Cited by 39
Evaluation of fatigue in inflammatory bowel disease - a useful tool in daily practice
Saraiva, S., Cortez-Pinto, J., Barosa, R., Castela, J., Moleiro, J., Rosa, I., da Siva, J. P., & Dias Pereira, A. (2019) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2019.1602669 · Cited by 22
Ulcerative colitis as a novel cause of increased need for levothyroxine
Virili, C., Stramazzo, I., Santaguida, M. G., Bruno, G., Brusca, N., Capriello, S., Cellini, M., Severi, C., Gargano, L., & Centanni, M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00233 · Cited by 20
Trindade, I. A., Pereira, J., Galhardo, A., Ferreira, N. B., Lucena-Santos, P., Carvalho, S. A., Oliveira, S., Skvarc, D., Rocha, B. S., Portela, F., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.699367 · Cited by 20
“Disease activity The Mayo Score (non-invasive 9-point partial Mayo Score; for ulcerative colitis participants) (82) and Harvey-Bradshaw Score (83) (for Crohn’s Disease participants) were analyzed considering assessments by participants and their physician.”
BackgroundKeegan, D., Byrne, K., Cullen, G., Doherty, G. A., Dooley, B., & Mulcahy, H. E. (2015) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjv120 · Cited by 19
Metadata
- Authors
- Lewis, J. D., Chuai, S., Nessel, L., Lichtenstein, G. R., Aberra, F. N., & Ellenberg, J. H.
- Venue
- Inflammatory Bowel Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-12
- Volume
- 14
- Issue
- 12
- Pages
- 1660-1666
- ISSN
- 1078-0998 (ISSN-L)
- OpenAlex
- W2031193040
- Cited by
- 964
- References
- 15
- FWCI
- 3.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.